Should I buy Krystal Biotech (KRYS) stock or is it too late?

Krystal Biotech · Health Care · price $357

See the full Krystal Biotech (KRYS) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: B of A Securities — 74% of its targets hit on this sector (105 calls tested). It aims for $396 (+11 %), call made on July 15, 2026, maturing on July 15, 2027 (44 d ago).

The 5 reliable analysts $396+11 %

The 1 other firm $300-16 %

How to read it: the 5 reliable firms are not filtered by optimism — 5 aim above the price, 0 below, hence their $396 median. “The 1 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Krystal Biotech

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Chardan Capital	93 %	+73.3 %	15	$323 -10%
Guggenheim	100 %	+55.3 %	6	$284 -21%
Cantor Fitzgerald	83 %	+53.3 %	6	$215 -40%
Goldman Sachs	90 %	+52.9 %	10	$327 -9%
HC Wainwright & Co.	70 %	+41.0 %	33	$361 +1%

In short — Should you invest in Krystal Biotech? Is it too late, still worth it? Analysts are overwhelmingly positive (86% buy, median target $391, i.e. +9%), and the most reliable on KRYS targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

86% of analysts rate it a buy (Buy consensus, 7 ratings) — a sign of market conviction.
Median price target $391, i.e. +9% from the current price ($357).
The most reliable firm on KRYS, B of A Securities (100% hit rate, 4 scored calls), targets $396 (call made on July 14, 2026, maturing on July 14, 2027) (+11%) in its most recent call, and $255 (call made on October 17, 2025, maturing on October 17, 2026) (-29%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 7 ratings, 1 is neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on KRYS

Median target $391 (+9%) · 7 ratings · Buy consensus

Strong Buy00%

Buy686%

Hold114%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Krystal Biotech now?

We won't decide for you. The facts: 86% of analysts rate it a buy, median target $391 (+9%), and B of A Securities (most reliable on KRYS, 100%) targets $396. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Krystal Biotech?

Not according to analysts: the median target ($391) is still +9% above the current price ($357) (most reliable on KRYS: B of A Securities, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Krystal Biotech still worth investing in?

It depends on the gap between the price ($357) and its estimated value: analysts target $391 on median (+9%), with 86% buys (most reliable on KRYS: B of A Securities, 100%). Cross-check with their real reliability on KRYS and the cautions above. Information, not advice.

What's the main risk in buying KRYS?

The consensus is not unanimous: of 7 ratings, 1 is neutral.

→ Go deeper: the full Krystal Biotech profile (consensus, analyst reliability, price target, performance).